The FDA apparently deems an uncontrolled study acceptable – five months after saying no.
ApexOnco Front Page
Recent articles
Could RO7851624, newly into clinical trials, be RG6735?
Early data on SSGJ-707 in PD-L1-positive lung cancer spur comparisons against ivonescimab.
DZD8586 shows some evidence that it can rescue BTK failures, but its precise role remains unclear.
In first-line renal cancer, zanzalintinib plus Opdivo has outshone Cabometyx plus Opdivo.
Gilead’s TROP2 ADC sets the bar for Astra/Daiichi’s Datroway in first-line TNBC.
Any hopes of differentiation could come down to side effects.
BNT142 looks lacklustre, but the company still sees promise in mRNA-encoded bispecifics.